Literature DB >> 21813543

IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis.

Elisabeth Diot1, Delphine Carmier2, David Marquette2, Sylvain Marchand-Adam3, Patrice Diot4, Vincent Lesire5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813543     DOI: 10.1378/chest.11-0492

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  8 in total

Review 1.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

2.  Novel approaches in the treatment of myositis and myopathies.

Authors:  Jemima Albayda; Lisa Christopher-Stine
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

Review 3.  [Myositides: What is the current situation?].

Authors:  K M Rösler; O Scheidegger
Journal:  Z Rheumatol       Date:  2015-08       Impact factor: 1.372

Review 4.  Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Authors:  Robert W Hallowell; Julie J Paik
Journal:  Clin Exp Rheumatol       Date:  2021-03-25       Impact factor: 4.473

Review 5.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

Review 6.  The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics.

Authors:  Anjali Patwardhan
Journal:  Cureus       Date:  2020-02-19

7.  Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease.

Authors:  Soran Peshbahar; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2020-10-26

Review 8.  Management of Myositis-Associated Interstitial Lung Disease.

Authors:  Tomoyuki Fujisawa
Journal:  Medicina (Kaunas)       Date:  2021-04-03       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.